Chardan Capital Reiterates “Buy” Rating for Unity Biotechnology (NASDAQ:UBX)
Unity Biotechnology (NASDAQ:UBX – Get Free Report)‘s stock had its “buy” rating reissued by Chardan Capital in a research note issued on Monday,Benzinga reports. They presently have a $6.00 price objective on the stock. Chardan Capital’s price target suggests a potential upside of 248.84% from the company’s current price. Separately, HC Wainwright restated a “buy” […]
Unity Biotechnology (NASDAQ:UBX – Get Free Report)‘s stock had its “buy” rating reissued by Chardan Capital in a research note issued on Monday,Benzinga reports. They presently have a $6.00 price objective on the stock. Chardan Capital’s price target suggests a potential upside of 248.84% from the company’s current price. Separately, HC Wainwright restated a “buy” […]
